难治性院外心脏骤停的机械循环支持:丹麦全国多中心研究
该回顾性观察性队列研究纳入2011年7月至2020年12月丹麦全部4个三级心脏骤停中心接受机械循环支持(MCS,体外膜氧合或Impella)的难治性院外心脏骤停(OHCA)患者259例。30天生存率为26%,65例(25%)存活至出院且神经功能良好(Glasgow-Pittsburgh脑功能分级1-2级),这些存活者中94%神经功能良好。严格遵循国家共识者30天生存率30%,违反一项或多项标准者为22%。在共识基础上增加心肺复苏期间有生命迹象、院前低流量时间<100 min、pH>6.8、乳酸<15 mmol/L等标准可将生存率提高至48%,但会排除当前队列中58%的存活者。
要点
- 丹麦全国4个中心259例难治性OHCA接受MCS,30天生存率26%,25%存活至出院且神经功能良好。
- 严格遵循国家共识者30天生存率30%,违反一项或多项标准者为22%。
- 增加心肺复苏期间有生命迹象、院前低流量<100 min、pH>6.8、乳酸<15 mmol/L可将生存率提至48%,但排除58%的存活者。
- 回归分析显示心脏停搏(RR 1.36,95%CI 1.18-1.57)、无脉电活动(RR 1.20,95%CI 1.03-1.41)、初始pH<6.8(RR 1.28,95%CI 1.12-1.46)、乳酸>15 mmol/L(RR 1.16,95%CI 1.16-1.53)与30天死亡风险增加相关。
- 心肺复苏期间有生命迹象者30天死亡风险降低(RR 0.63,95%CI 0.52-0.76)。
适用人群与场景
- 2011年7月至2020年12月丹麦全部4个三级心脏骤停中心接受MCS(体外膜氧合或Impella)治疗的难治性院外心脏骤停患者。
诊断标准与关键阈值
- 国家共识标准:原文未列出具体条目,仅报告严格遵循与违反一项或多项标准的生存差异。
- 研究额外分析的标准:心肺复苏期间有生命迹象、院前低流量时间<100 min、pH>6.8、乳酸<15 mmol/L。
处置流程与药物剂量
- MCS方式包括体外膜氧合或Impella,具体剂量、流程原文未报告。
研究设计与关键结果
- 回顾性观察性队列研究,纳入丹麦4个三级心脏骤停中心259例接受MCS的难治性OHCA患者。
- 30天生存率26%;65例(25%)存活至出院且神经功能良好(Glasgow-Pittsburgh脑功能分级1-2级),这些存活者中94%神经功能良好。
- 严格遵循国家共识者30天生存率30%,违反一项或多项标准者为22%。
- 在共识基础上增加心肺复苏期间有生命迹象、院前低流量<100 min、pH>6.8、乳酸<15 mmol/L可将生存率提高至48%,但会排除当前队列中58%的存活者。
- 多因素回归:心脏停搏(RR 1.36,95%CI 1.18-1.57)、无脉电活动(RR 1.20,95%CI 1.03-1.41)、初始pH<6.8(RR 1.28,95%CI 1.12-1.46)、乳酸>15 mmol/L(RR 1.16,95%CI 1.16-1.53)与30天死亡风险增加相关;心肺复苏期间有生命迹象与30天死亡风险降低相关(RR 0.63,95%CI 0.52-0.76)。
证据类型、等级与局限
- 证据类型:回顾性观察性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,对MCS进行严格的患者选择可能产生更高的生存率,但可能使相当比例的存活者失去挽救生命的治疗。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Mechanical circulatory support (MCS) with either extracorporeal membrane oxygenation or Impella has shown potential as a salvage therapy for patients with refractory out-of-hospital cardiac arrest (OHCA). The objective of this study was to describe the gradual implementation, survival and adherence to the national consensus with respect to use of MCS for OHCA in Denmark, and to identify factors associated with outcome.
METHODS: This retrospective, observational cohort study included patients receiving MCS for OHCA at all tertiary cardiac arrest centers (n = 4) in Denmark between July 2011 and December 2020. Logistic regression and Kaplan-Meier survival analysis were used to determine association with outcome. Outcome was presented as survival to hospital discharge with good neurological outcome, 30-day survival and predictors of 30-day mortality.
RESULTS: A total of 259 patients were included in the study. Thirty-day survival was 26%. Sixty-five (25%) survived to hospital discharge and a good neurological outcome (Glasgow-Pittsburgh Cerebral Performance Categories 1-2) was observed in 94% of these patients. Strict adherence to the national consensus showed a 30-day survival rate of 30% compared with 22% in patients violating one or more criteria. Adding criteria to the national consensus such as signs of life during cardiopulmonary resuscitation (CPR), pre-hospital low-flow < 100 min, pH > 6.8 and lactate < 15 mmol/L increased the survival rate to 48%, but would exclude 58% of the survivors from the current cohort. Logistic regression identified asystole (RR 1.36, 95% CI 1.18-1.57), pulseless electrical activity (RR 1.20, 95% CI 1.03-1.41), initial pH < 6.8 (RR 1.28, 95% CI 1.12-1.46) and lactate levels > 15 mmol/L (RR 1.16, 95% CI 1.16-1.53) as factors associated with increased risk of 30-day mortality. Patients presenting signs of life during CPR had reduced risk of 30-day mortality (RR 0.63, 95% CI 0.52-0.76).
CONCLUSIONS: A high survival rate with a good neurological outcome was observed in this Danish population of patients treated with MCS for OHCA. Stringent patient selection for MCS may produce higher survival rates but potentially withholds life-saving treatment in a significant proportion of survivors.
参考来源
- Mørk SR, Stengaard C, Linde L, et al. Mechanical circulatory support for refractory out-of-hospital cardiac arrest: a Danish nationwide multicenter study. Crit Care. 2021. PMID: 34022934. doi:10.1186/s13054-021-03606-5
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。